Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
-
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March
-
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
-
VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
-
VistaGen Therapeutics Announces Exercise and Closing of Underwriters' Over-allotment Option in Underwritten Public Offering
-
VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering
-
VistaGen Therapeutics (VTGN) Prices 15.625M Share Common Offering at $0.80/Sh
-
VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock
-
VistaGen Therapeutics (VTGN) Commences Public Offering of Common Stock
-
VistaGen Therapeutics Announces Proposed Public Offering of Common Stock
-
VistaGen Therapeutics (VTGN) PT Lowered to $1 at Maxim Group
-
VistaGen Therapeutics (VTGN) Should Benefit From Positive Spravato Recommendation - Maxim
-
Maxim Group Starts VistaGen Therapeutics (VTGN) at Buy
-
Maxim Group Starts VistaGen Therapeutics (VTGN) at Buy
